Editors' note: Evaluating depression and suicidality in tetrabenazine users with Huntington disease

After a 2006 randomized clinical trial of 84 patients identified suicidality in 2 tetrabenazine (TBZ) users, the Food and Drug Administration issued a black box warning for this Huntington disease (HD) medication. Using the retrospective Enroll-HD database, Schultz et al. sought to clarify this relationship in a larger cohort.

Source link

Back to top button